A systematic review of the characteristics of randomised control trials featuring prostaglandins for the treatment of glaucoma

Current Medical Research and Opinion

Volumn 24, Issue 8, 2008, Pages 2265-2270

  Lee, Chia Wen ^a   Buckley, F ^b   Costello, S ^b   Kelly, S ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b Heron Evidence Development Ltd   (United Kingdom)

Author keywords

Bimatoprost; Glaucoma; Latanoprost; Prostaglandins; Randomised controlled trial; Travoprost

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BIMATOPROST; BRIMONIDINE; BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; CARTEOLOL; DIPIVEFRINE; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; LATANOPROST PLUS TIMOLOL; LEVOBUNOLOL; METIPRANOLOL; MIOTIC AGENT; PILOCARPINE; PROSTAGLANDIN; TIMOLOL MALEATE; TRAVOPROST;

CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; GLAUCOMA; HUMAN; HYPEREMIA; INTRAOCULAR PRESSURE; MEDICAL LITERATURE; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW;

AGED; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MIDDLE AGED; OCULAR HYPERTENSION; PROSTAGLANDINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 50149087512     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802273652     Document Type: Review

References (25)

1. WHO. Glaucoma is the second leading cause of blindness globally. http://www.who.int/bulletin/volumes/82/11/feature1104/en/print.html. 2004. Ref Type: Internet Communication
2. Boland MV, Quigley HA. Risk factors and open-angle glaucoma: classification and application. J Glaucoma 2007;16:406-18
3. Tuck MW, Crick RP. The projected increase in glaucoma due to an ageing population. Ophthalmic Physiol Opt 2003;23:175-9
4. Mein BE, Klein R, Sponsel WE, et al. Prevalence of glaucoma. The Beaver Dam Eye Study. Ophthalmology 1992;99:1499-504
5. Leske MC, Connell AM, Schachat AP, et al. The Barbados Eye Study. Prevalence of open angle glaucoma. Arch Ophthalmol 1994;112:821-9
6. Royal College of Ophthalmologists. Guidelines for the management of open angle glaucoma and ocular hypertension. http://www.rcophth.ac.uk/about/ publications/2004
7. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12
8. Carpineto P, Ciancaglini M, Zuppardi E, et al. The role of the uveoscleral outflow in the management of pigmentary glaucoma: a 24-month study comparing latanoprost with timolol. Acta Ophthalmol Scand 2000;(Suppl 232):54
9. Polo V, Larrosa JM, Gomez ML, et al. Latanoprost versus combined therapy with timolol plus dorzolamide: IOP-lowering effect in open-angle glaucoma. Acta Ophthalmol Scand 2001; 79:6-9
10. Ritch R. The International Collaborative Exfoliation Syndrome (XFS) Treatment Study (ICEST): study design, methods, an baseline data of enrolled patients. (2004). IOVS. 2004. Ref Type: Abstract
11. Tomita G, Araie M, Kitazawa Y, et al. A three-year prospective, randomized and open comparison between latanoprost and timolol in Japanese normal-tension glaucoma patients. Eye 2004;18:984-9
12. Ang A, Reddy MA, Shepstone L, et al. Long term effect of latanoprost on intraocular pressure in normal tension glaucoma. Br J Ophthalmol 2004;88:630-4
13. Waldock A, Snape J, Graham CM. Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients. Br J Ophthalmol 2000; 84:710-3
14. Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension [The Latanoprost Study Group]. Ophthalmology 1996;103:126-37
15. Akarsu C, Bilgili YK, Taner P, et al. Short-term effect of latanoprost on ocular circulation in ocular hypertension. Clin Experiment Ophthalmol 2004;32:373-7
16. Erkin EF, Tarhan S, Kayikcioglu OR, et al. Effects of betaxolol and latanoprost on ocular blood flow and visual fields in patients with primary open-angle glaucoma. Eur J Ophthalmol 2004; 14:211-9
17. Mastropasqua L, Carpineto P, Ciancaglini M, et al. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma. Ophthalmology 1999; 106:550-5
18. Kitnarong N, Zhao Y, Netland PA, et al. Efficacy of latanoprost and timolol maleate in black and white patients. Adv Ther 2004;21:203-13
19. Orzalesi N, Rossetti L, Invernizzi T, et al. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 2000;41:2566-73
20. Orzalesi N, Rossetti L, Bottoli A, et al. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch Ophthalmol 2003;121:453-7
21. Denis P, Lafuma A, Khoshnood B, et al. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy. Curr Med Res Opin 2007;23:601-8
22. Hodge WG, Lachaine J, Steffensen I, et al. The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review. Br J Ophthalmol 2008;92:7-12
23. Holmstrom S, Buchholz P, Walt J, et al. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Curr Med Res Opin 2005;21:1875-83
24. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study. Clin Ther 2003;25:1172-85
25. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Oplathalmol 2004;137(Suppl 1):S3-S12